BioCentury
ARTICLE | Company News

Debiopharm S.A., AstraZeneca deal

October 23, 2006 7:00 AM UTC

Debiopharm granted AZN subsidiary Cambridge Antibody Technology Group plc exclusive worldwide rights to develop and commercialize SC-1 and derivatives to treat gastric cancer. Debiopharm will receiv...